Explore ViiV Healthcare
Our Executive Team
Deborah Waterhouse became Chief Executive Officer of ViiV Healthcare on 1st April 2017. She has been CEO Designate since 1st January 2017.
Deborah joined GSK in 1996 and was most recently the Senior Vice President of Primary Care within the company’s US business, prior to which she led the US Vaccines business. She brings a wealth of experience to ViiV Healthcare having lived and worked in Europe, Asia and the USA, and a strong track record of performance in both specialty and primary care. Deborah led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and Senior Vice President for Central and Eastern Europe.
Jill Anderson became our Chief Financial Officer on 1 August 2018.
Jill joined the ViiV Executive Team from GSK where she was VP Franchise Finance, Global Pharmaceutical and brings more than 25 years of experience working in the industry. She has held a broad range of roles of increasing responsibility across Finance, Commercial, R&D and Manufacturing. In her most recent role, Jill was accountable for leading the finance partnering on global commercial strategy, R&D financial investment appraisal, long range sales planning and profit optimisation across the portfolio lifecycle.
At the beginning of her career, Jill received her accounting qualification at Shell International Petroleum Company. She holds a degree in Chemistry from the University of Exeter, has been a school governor and is an active sponsor of the Accelerating Difference diversity programme in GSK.
Jocelyn Brown is our global Head of HR and joined ViiV Healthcare from GSK in 2016.
Jocelyn developed her career at GSK since 2002, where she held various HR positions of increasing seniority working in UK Pharma, Consumer Healthcare, GMS, and the HR Talent and Leadership Centre of Excellence. In her most recent role prior to joining ViiV Healthcare Jocelyn supported several GSK Corporate Executive Team members and their leadership teams to deliver change, capability building and talent programmes across the Global Ethics and Compliance and Communications and Government Affairs functions, as well as Global Corporate Development, Corporate Secretariat and the Office of the CEO.
Jocelyn is responsible for delivering HR strategy across ViiV Healthcare, supporting leaders and employees to continue guiding the business through a continued period of growth, develop capability and talent underpinned by our company’s unique culture.
Jocelyn holds a degree in History & Management Studies from the University of Glasgow, Scotland.
Eric Dube brings nearly 20 years of pharmaceutical leadership experience to head ViiV Healthcare’s operations in the US, Canada and Puerto Rico.
Eric began his career at GSK in 2000 as a medical science liaison and has worked in a variety of marketing, sales, operations and strategy roles in the US, Japan and Europe. He served as vice president of managed markets for national accounts, as well as head of the oncology business unit where he oversaw multiple product launches and transformed the business model to better address emerging customer and patient needs. He then led commercial operations across the North America Pharma organization as senior vice president of strategy, planning and operations.
In 2013, Eric joined GSK Japan as senior vice president and head of the 800-person respiratory business unit. Under his leadership, GSK Japan’s respiratory portfolio and business returned to growth. Most recently, as senior vice president and head of the global respiratory franchise, Eric established a 10-year strategic plan for the global respiratory portfolio focused on delivering sustained growth.
During his tenure at GSK, Eric was the co-sponsor of the Women’s Leadership Initiative employee resource group and various diversity leadership development programs, and served on the Global LGBT+ Council. He currently represents ViiV Healthcare on the GSK US Race and Ethnicity Council.
Eric’s leadership has earned national and global recognition. He was on Fortune magazine’s “40 Under 40: Ones to Watch” list in 2011 and was named one of 2012’s “Emerging Pharma Leaders” by Pharmaceutical Executive. He was also featured on the Financial Times’ list of “OUTstanding 100 LGBT+ Executives” in 2018.
Eric’s professional focus on addressing unmet needs of patients and customers has also influenced his personal interests. He served as a founding member of the board of directors for Puentes de Salud, a non-profit that promotes the health and wellness of Philadelphia’s Latino immigrant population. More recently, Eric joined the board of trustees for AIDS United, an organization committed to ending the AIDS epidemic in the US through strategic grantmaking, capacity building, and policy/advocacy.
After graduating cum laude from Santa Clara University with a B.S. in Biopsychology, Eric earned an M.A. and Ph.D. in Psychology from Cornell University, where his studies focused on how culture, gender and ethnicity influenced resilience in the LGBTQ community. He also completed the Finance for Senior Executives program at Harvard Business School and studied four languages.
Currently lead for the ViiV Healthcare Discovery organisation, Mark Cockett is responsible for delivering new HIV drug candidates that are aligned to future medical needs into clinical development; and providing research support for clinical development assets as they progress in the clinic.
Mark joined ViiV Healthcare in February this year with the acquisition of Bristol-Myers Squibb (BMS) HIV pipeline assets. Previously Mark was VP of Discovery Infectious Diseases at BMS (2008-2016), responsible for delivery of antiviral therapeutics into the pipeline. His team at BMS has delivered marketed products targeting HIV, HBV and HCV as well as the pipeline of HIV drugs recently acquired by ViiV Healthcare. Prior to this at BMS Mark was VP, Applied Genomics (2003-2008) and Executive Director, Functional Genomics (2000-2003) and in those roles led a team that supported all therapeutic areas with genomics technologies and bioinformatics.
Before joining BMS, Mark worked for 7 years in the Neuroscience group at Wyeth, ultimately as Director, molecular & cell biology, and for 10 years in the biotech industry for Celltech PLC, where he worked on mammalian gene expression technology and in oncology. Whilst at Celltech he obtained his Ph.D. in collaboration with the Strangeway Research Laboratory, Cambridge, UK working on the involvement of matrix metalloproteinases in tumour cell invasion.
Mark has published over 50 peer reviewed articles in the field of recombinant gene expression in mammalian cells; the biochemistry and function of several matrix metalloproteinase enzymes and their role in disease; in the field of heterotrimeric G protein signaling; Genomics in the pharmaceutical industry and most recently several virology publications.
Aggie Gallagher is Vice President, Head of ViiV Healthcare Legal and Compliance and joined the ViiV Healthcare Executive Team (VET) on 24th April 2017.
Aggie joined GSK in 2013 as Assistant General Counsel providing strategic legal leadership to Global Vaccines Commercial Global Government Affairs, Public Policy, Patient Advocacy and Communications. She then led the Novartis integration for Vaccines before she was promoted to Vice President, Ethics and Compliance Officer, Vaccines in 2015 to head up risk management and compliance for Vaccines as a member of the Vaccines Executive Team. Prior to joining GSK Aggie held senior Legal roles at Pfizer, Sandoz and Medtronic.
In 2005, Harmony joined the Infectious Diseases group at GSK and spent several years working on global development programs, as project physician leader for Fosamprenavir, Valtrex and Altabax, leading to three successful NDA/MAA files for new or expanded indications. Harmony provided medical leadership and strategy for the development of various other anti-infectives through phases I to III, including the FTIH dolutegravir trial.
She then joined Global Clinical Safety & Pharmacovigilance, where she provided safety strategy and governance for several large global clinical development programs in Pharma, and as Global VP of the Mature Products Safety Group, with accountability for the safety of over 500 marketed products across the Pharma and Consumer Healthcare (CH) portfolio. Harmony spent three years as the Chief Medical Officer for GSK's Consumer Healthcare business, where she was accountable for all aspects of product safety and medical governance for the global portfolio, and led the medical organisation though the complex JV integration with Novartis.
Harmony graduated with high honors from Colgate University with a degree in Chemistry. She obtained her MD degree and completed her pediatrics residency at Duke University. Following a year as Chief Resident, she completed pediatric infectious diseases and Medical Microbiology fellowships at Duke, along with her MPH in Epidemiology from the University of North Carolina at Chapel Hill.
Harmony is board-certified in General Pediatrics, Medical Microbiology and Pediatrics Infectious Diseases. Harmony is Adjunct Faculty at Duke, where she continues to provide patient care in the Duke Pediatric HIV/ clinic.
Dr John Pottage is our Chief Scientific and Medical Officer. He oversees R&D, Regulatory, Safety and Medical Affairs.
John is the former SVP, Infectious Diseases Medicine Development Centre for GSK. John previously held senior positions at Vertex Pharmaceuticals and Achillion Pharmaceuticals, where he helped lead a successful IPO in 2006 and led the HIV and HCV development programmes. Before joining the pharmaceutical industry, John was Associate Professor of Internal Medicine in the Section of Infectious Diseases at Rush Medical College in Chicago. While at Rush, he was Director of the Outpatient HIV Centre.
John is board certified in both Internal Medicine and Infectious Disease. He is the author of more than 50 peer-reviewed medical articles as well as the author of several chapters in Infectious Disease textbooks.
Stephen Rea is Head of External Affairs and Communications.
Stephen started his career at GSK in 2005, where he joined as a Government Affairs Director in the UK. He then took further roles of growing responsibilities in the Corporate Media and Global Public Health teams, where he leveraged GSK's leadership in Global Public Health to drive improved access to medicines and vaccines and to implement the introduction of world's first pneumococcal and rotavirus vaccines into sub-Saharan Africa. He also worked in the US for three years, leading Communications and Government Affairs for the US Pharmaceuticals business, as a member of the Executive Team.
In his previous role, Stephen led a global team for two years to drive the reputation of GSK's Consumer Healthcare business through the successful transition and on-boarding of the Consumer Healthcare CEO and driving the integration work following the Novartis deal.
Prior to joining GSK, he worked for Shell International, as well as for a communications consultancy, after three years as a journalist for the BBC. Stephen holds a postgraduate diploma in Broadcast Journalism from Cardiff University.
As the head of global research and medical strategy for ViiV Healthcare, Dr. Kimberly Smith MD, MPH oversees the clinical development of our pipeline assets in support of our overall company strategy to deliver meaningful advances in treatment and care for people living with HIV.
Dr. Smith is a graduate of the University of Michigan School of Medicine and also holds a MPH degree from the University of Michigan School of Public Health. She completed her internship, residency, and Infectious Disease fellowship at Rush University Medical Centre in Chicago. Following her training she joined the faculty of the Section of Infectious Disease at Rush University Medical Center in Chicago.
Prior to joining ViiV Healthcare in late 2013, Dr. Smith served as the Principle Investigator of the Rush University Medical Center Clinical Research Site of the AIDS Clinical Trials Group (ACTG). Dr. Smith also served as the chair of the ACTG Underrepresented Populations committee and chair of multiple ACTG clinical trials. She has been a member of NIH study sections, the HIVMA Board of Directors, the CDC Board of Scientific Counselors and numerous advisory committees. Dr. Smith has published over 100 articles, abstracts and manuscripts and she co-edited one of the few books, HIV/AIDS in U.S. Communities of Color, which addressed the HIV epidemic among minorities in the US.
In addition to her research activities Dr. Smith has been an active HIV clinician, clinical educator, community leader and advocate. She has lectured at countless local national and international conferences including the Conference on Retroviruses and Opportunistic Infections (CROI), the International AIDS Conference, The International Conference on Antimicrobial Agents and Chemotherapy, and Infectious Disease Society of America.
Tim Tordoff is Senior Vice President & Head of Europe, having joined ViiV Healthcare from GSK in June 2013. He has overall accountability for the ViiV Healthcare business across Europe, which includes nine ViiV countries and 21 GSK Alliance markets. Tim joined GSK in 1993 and held senior roles within the respiratory organisation as Head of Global Commercial strategy and creating the Respiratory Centre of Excellence in Pharma Europe before being appointed General Manager, GSK Ireland in 2005. In this role, which included responsibility for the HIV business in the market, Tim drove a step change in government understanding and engagement with GSK. Following this, he was appointed Vice President Primary Care, and was instrumental in focusing the customer facing teams on launch and growth brands in a rapidly changing UK customer environment. This led to the successful launch of four medicines in 18-months. His last role in GSK before joining ViiV Healthcare was Vice President Service Development Core Business Services, during which he was able to create significant value for the GSK business through the establishment of a global network of Business Service Centres to deliver more customer focused services, leading Global Digital Services and setting up the Mergers, Acquisition and Divestment team.
Gregory Reinaud is Head of Global Commercial Strategy, including global product strategy for new and marketed products and commercial portfolio management. Before taking the role of Country Manager in Canada in 2011, where he successfully led the team for three years with a key focus on the launches of Tivicay and Triumeq, Greg started his career at ViiV Healthcare as the Executive Manager to Dominique Limet and the VET, at the creation of ViiV Healthcare.
Prior to joining ViiV Healthcare, he was a management consultant focused on healthcare with McKinsey & Co. He also worked at the UK Treasury and MTV. Greg is a graduate in Natural Sciences from Cambridge University in the UK and holds an MBA from INSEAD.
Craig Williams is our Head of International since 1 September 2018.
Prior to his appointment in ViiV Healthcare, Craig held positions in the US, Europe and Emerging Markets for GSK. He demonstrated consistent success and learning agility, progressing from Sales Representative to VP, leading commercial operations in over 50 markets and across all GSK portfolios. During his career, Craig has been a part of successfully launching more than 15 new medicines in countries around the world.
Known for his engaging leadership style, Craig has played a huge role in supporting diversity inclusion and global development programmes for key talent.